Juno Therapeutics, Inc. (NASDAQ:JUNO) insider Sunil Agarwal sold 7,285 shares of the stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $44.76, for a total value of $326,076.60. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Juno Therapeutics, Inc. (NASDAQ JUNO) traded down 0.42% during midday trading on Wednesday, reaching $44.91. The company’s stock had a trading volume of 892,780 shares. The stock’s market cap is $4.71 billion. Juno Therapeutics, Inc. has a one year low of $17.52 and a one year high of $47.03. The stock’s 50 day moving average price is $39.68 and its 200-day moving average price is $29.14.

Juno Therapeutics (NASDAQ:JUNO) last posted its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.96) EPS for the quarter, missing the consensus estimate of ($0.72) by ($0.24). Juno Therapeutics had a negative net margin of 354.36% and a negative return on equity of 27.10%. The business had revenue of $21.30 million during the quarter, compared to analysts’ expectations of $15.59 million. During the same period in the previous year, the company posted ($0.64) earnings per share. Juno Therapeutics’s revenue for the quarter was down 22.8% compared to the same quarter last year. On average, analysts forecast that Juno Therapeutics, Inc. will post ($3.12) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This news story was posted by American Banking News and is owned by of American Banking News. If you are accessing this news story on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/10/04/juno-therapeutics-inc-juno-insider-sells-326076-60-in-stock.html.

JUNO has been the topic of several research analyst reports. Wedbush raised Juno Therapeutics from a “neutral” rating to an “outperform” rating and set a $42.00 price target on the stock in a report on Tuesday, August 29th. Wells Fargo & Company reaffirmed an “outperform” rating and issued a $54.00 target price (up from $35.00) on shares of Juno Therapeutics in a report on Tuesday, September 5th. Raymond James Financial, Inc. raised Juno Therapeutics from a “market perform” rating to an “outperform” rating and set a $45.00 target price on the stock in a report on Tuesday, August 29th. Standpoint Research reaffirmed a “reduce” rating on shares of Juno Therapeutics in a report on Thursday, August 31st. Finally, Vetr raised Juno Therapeutics from a “sell” rating to a “hold” rating and set a $28.85 target price on the stock in a report on Monday, July 10th. Three research analysts have rated the stock with a sell rating, six have given a hold rating and nine have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $34.88.

Several institutional investors have recently modified their holdings of the business. Ardsley Advisory Partners acquired a new position in shares of Juno Therapeutics in the second quarter worth about $299,000. Broadfin Capital LLC raised its position in shares of Juno Therapeutics by 49.2% in the second quarter. Broadfin Capital LLC now owns 262,100 shares of the biopharmaceutical company’s stock worth $7,834,000 after acquiring an additional 86,400 shares during the period. Wasatch Advisors Inc. acquired a new position in shares of Juno Therapeutics in the second quarter worth about $19,787,000. Public Employees Retirement System of Ohio raised its position in shares of Juno Therapeutics by 115.3% in the second quarter. Public Employees Retirement System of Ohio now owns 56,326 shares of the biopharmaceutical company’s stock worth $1,684,000 after acquiring an additional 30,170 shares during the period. Finally, Tower Research Capital LLC TRC raised its position in shares of Juno Therapeutics by 809,500.0% in the second quarter. Tower Research Capital LLC TRC now owns 16,192 shares of the biopharmaceutical company’s stock worth $484,000 after acquiring an additional 16,190 shares during the period. Institutional investors and hedge funds own 67.38% of the company’s stock.

About Juno Therapeutics

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Insider Buying and Selling by Quarter for Juno Therapeutics (NASDAQ:JUNO)

Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.